The Mechanism of Action of Palbociclib
Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6
Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, explains the mechanism of palbociclib, a novel oral selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Clinical Pearls:
- By inhibiting CDK 4 and 6, the agent prevents DNA synthesis by prohibiting progression from G1 to S phase of the cell cycle
- The agent also inhibits phosphorylation of the RB protein
- Palbociclib prohibits cell proliferation
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Durability and Intracranial Efficacy Observed With T-DXd in HER2+ MBC
January 13th 2025During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.
Read More
